Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX056 vs Baclofen IR for Spasticity in Multiple Sclerosis
NCT00914290Phase 2Completed
- Sponsor
- Impax Laboratories
- Start
- Apr 2009
- Primary completion
- Jan 2010
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of IPX056 in spasticity, sponsored by Impax Laboratories. Started Apr 2009; status: completed.
02
Drugs
IPX056
03
Conditions
spasticity
Beyond the preview
Go deeper on NCT00914290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00914290.